Caris Life Sciences (CAI) Director Jon Halbert Buys 68,000 Shares

What Happened
Jon Halbert, a director of Caris Life Sciences (CAI), acquired 68,000 shares in open-market purchases on May 15, 2026. The reported weighted-average price was $14.56 per share, for a total reported outlay of approximately $990,080. The filing lists the transaction code P (purchase), indicating a buy rather than a sale.

Key Details

• Transaction date: 2026-05-15 (reported in Form 4 filed 2026-07-13).
• Price: weighted average $14.56; purchases occurred at prices ranging $14.49–$14.60 (report states detailed breakdown available on request).
• Shares acquired: 68,000; reported total value ≈ $990,080.
• Footnotes: the report notes aggregates of 23,196 shares and 11,598 shares received in pro rata distributions exempt under Rule 16a-9; the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
• Shares owned after transaction: not disclosed in the provided excerpt.
• Timeliness: the Form 4 was filed on 2026-07-13 for a 2026-05-15 transaction, which is later than the typical two-business-day filing window and may reduce timeliness of public disclosure.

Context
Open-market purchases by directors are typically treated by investors as a direct purchase of stock (a bullish signal relative to sales), but filings don't reveal motivation. The footnotes indicate some reported share counts include pro rata distributions exempt under Rule 16a-9 (these distributions are not open-market buys). The reporting person has offered to supply a price-by-price breakdown on request, per the Form 4.